The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC)

Results from a prospective observational reference laboratory testing programView graphical summary page of abstract  

Labcorp Announces 2023 Second Quarter Results

Company Provides Full-Year Guidance Labcorp completed the spin-off of Fortrea on June 30 , which is treated as discontinued operations in the historical financials Announced a $1.0 billion accelerated share repurchase program Drove growth through new and expanded healthcare system partnerships

Labcorp OnDemand Offers Menopause Test to Consumers

Labcorp's Menopause Test and Menopause Support Program provide women with insights to guide their healthcare decisions BURLINGTON, N.C. , July 24, 2023 /PRNewswire/ --  Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it now offers menopause

First-in-human (FIH) phase I dose escalation study (Part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in Uveal Melanoma (Part B)

First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors

Prevalence of KRAS p.G12C mutation in patients with metastatic non-small cell lung cancer in Argentina

Site of metastasis and its impact on clinical outcomes in 8 cancer cohorts

LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics